Loading
IT
Invivo Therapeutics Holdings Corp. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Foose Brice, was filed 07 Feb 2024.
Invivo Therapeutics Holdings Corp.: what insiders have been doing
Invivo Therapeutics Holdings Corp. is a Healthcare & Pharma company. Its directors and officers file their transactions with SEC (Form 4). Invivo Therapeutics Holdings Corp. has had no insider filing for more than a year; the last one goes back to 7 February 2024.
Since 2016, the database holds 14 purchases and 1 sale by insiders of the company.
Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
35
Thresholds
n/a
Buy Volume
€113,551
14 ops. · all time
Sell Volume
€4,507
1 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2022FY ended December 2022 · cache
Income statement
Net income-US$9M
Last declaration on 7 February 2024
Declarations35 total
20,000 shares@ US$0.32InVivo Therapeutics Holdings CorpSEC:0001974830-24-000001:1
Canonical exit: 6 May 2023 (T+90)
13,000 shares@ US$0.30InVivo Therapeutics Holdings CorpSEC:0001974830-24-000001:2
Canonical exit: 6 May 2023 (T+90)
48,000 shares@ US$0.28InVivo Therapeutics Holdings CorpSEC:0001974830-24-000001:3
Canonical exit: 6 May 2023 (T+90)
12,000 shares@ US$0.25InVivo Therapeutics Holdings CorpSEC:0001974830-24-000001:4
Canonical exit: 6 May 2023 (T+90)
36,000 shares@ US$0.26InVivo Therapeutics Holdings CorpSEC:0001974830-24-000001:5
Canonical exit: 6 May 2023 (T+90)
8,000 shares@ US$0.34InVivo Therapeutics Holdings CorpSEC:0001974830-24-000001:6
Canonical exit: 7 May 2023 (T+90)
33,000 shares@ US$0.35InVivo Therapeutics Holdings CorpSEC:0001974830-24-000001:7
Canonical exit: 7 May 2023 (T+90)
35,000 shares@ US$0.36InVivo Therapeutics Holdings CorpSEC:0001974830-24-000001:8
Canonical exit: 7 May 2023 (T+90)
37,000 shares@ US$0.50InVivo Therapeutics Holdings CorpSEC:0001974830-24-000001:9
Canonical exit: 7 May 2023 (T+90)
51,000 shares@ US$0.59InVivo Therapeutics Holdings CorpSEC:0001974830-24-000001:10
Canonical exit: 7 May 2023 (T+90)
37,000 shares@ US$0.3150.0% of flowInVivo Therapeutics Holdings CorpSEC:0001974830-24-000001:0
Canonical exit: 6 May 2023 (T+90)
16 shares@ US$0.5437.0% of flowCommon StockSEC:0001179110-21-011222:0
21 shares@ US$0.7463.0% of flowCommon StockSEC:0001179110-21-007020:0
16 shares@ US$0.6015.3% of flowCommon StockSEC:0001179110-20-012218:0
15 shares@ US$1.7017.3% of flowCommon StockSEC:0001179110-20-007730:0
3,636 sharesCommon StockSEC:0001179110-20-003589:0
Canonical exit: 8 Jun 2020 (T+90)
3,636 sharesCommon StockSEC:0001179110-20-003591:0
Canonical exit: 8 Jun 2020 (T+90)
3,636 sharesCommon StockSEC:0001179110-20-003590:0
Canonical exit: 8 Jun 2020 (T+90)
557 shares@ US$0.161.2% of flowCommon StockSEC:0001179110-19-013127:0
69,000 shares0Common StockSEC:0001179110-19-010714:0
47,500 shares0Common StockSEC:0001179110-19-010713:0
5,229 shares@ US$0.9767.8% of flowCommon StockSEC:0001179110-19-010715:0
72 shares@ US$0.750.7% of flowCommon StockSEC:0001179110-19-008009:0
78 shares@ US$1.101.2% of flowCommon StockSEC:0001179110-19-006512:0
79 shares@ US$1.451.5% of flowCommon StockSEC:0001179110-19-005165:0
25 of 35 declarations
About Invivo Therapeutics Holdings Corp.
InVivo Therapeutics Holdings Corp. is a U.S.-based biomaterials and biotechnology company listed on the NASDAQ market in the United States. The company is highly specialized: it focuses on the treatment of spinal cord injuries and, more broadly, on regenerative and biomaterial-based approaches aimed at addressing a severe unmet medical need. For international investors, this is a classic small-cap healthcare innovation profile, where valuation is driven primarily by scientific progress, clinical milestones, regulatory developments, and financing capacity rather than by a broad base of mature product sales.
The company has a long development history in U.S. biotech. The publicly listed vehicle was redirected toward the InVivo business after the acquisition of InVivo Therapeutics Corporation in 2010; the operating business itself was founded in 2005. SEC filings also note that the company’s proprietary technology was co-invented in connection with leading academic institutions, including the Massachusetts Institute of Technology and Boston Children’s Hospital, which helped establish early scientific credibility. Its headquarters are in Cambridge, Massachusetts, a core life-sciences hub and an important ecosystem for biomedical research and talent.
Read moreShow less
From a business-model perspective, InVivo remains primarily an R&D-stage company. Its core activity is the development of technologies and biomaterial solutions for spinal cord injury, with a platform-oriented strategy rather than a diversified commercial product portfolio. That means the company does not, at this stage, rely on large-scale recurring product revenues. Its key strategic assets are its intellectual property, scientific know-how, and clinical development capabilities. As a result, its competitive position is that of a niche innovator: potentially differentiated by its technology and scientific focus, but facing meaningful competition from pharmaceutical approaches, medical device developers, and alternative regenerative medicine strategies.
Geographically, the company’s footprint is mainly U.S.-centered, with its operating base in Cambridge, Massachusetts. That said, like many clinical-stage life-science companies, it may engage in broader regulatory, research, and collaboration activities that can extend beyond the United States. Recent items of market relevance for investors include SEC Form 4 insider transaction reporting, as well as standard public-company disclosures and market-compliance developments. Because the stock trades on NASDAQ, liquidity, ongoing listing compliance, and the company’s ability to access capital remain critical factors when assessing the investment case.
In short, InVivo Therapeutics should be viewed as a focused, high-risk/high-potential biotech platform anchored in spinal cord injury innovation, with value creation dependent on execution, data generation, and balance-sheet discipline rather than scale economics.
